HOX11 Antibody

What is HOX11 and what are its biological functions?

HOX11 (TLX1) is an evolutionarily conserved transcription factor that plays critical roles in both embryonic development and adult tissues. During embryogenesis, HOX11 is required for normal development of the spleen and is involved in specification of neuronal cell fates . In adult tissues, Hox11-expressing cells function as skeletal stem cells that arise from the earliest stages of skeletal development and self-renew throughout life, maintaining critical roles in the adult skeleton .

HOX11 has gained significant attention in cancer research due to its involvement in T-cell acute lymphoblastic leukemia (T-ALL). The gene can be aberrantly activated by chromosomal translocations, specifically t(7;10) and t(10;14), though studies have shown that HOX11 expression can occur at high levels (19.7% of pediatric T-ALL cases) or low levels (28.9% of cases) even without detectable chromosomal rearrangements at 10q24 . Interestingly, high HOX11 expression in leukemic blasts has been associated with better clinical outcomes in certain patient subgroups, suggesting its potential value as a prognostic marker .

What types of HOX11 antibodies are available for research?

Several types of HOX11 antibodies are commercially available for research applications:

• Polyclonal rabbit antibodies: These recognize various epitopes of the HOX11 protein and are available in different formats:

  • Azide and BSA-free formats (e.g., NBP3-03317) generated against recombinant fusion proteins containing amino acids 1-190 of human HOX11

  • BSA-free formats (e.g., NB100-56424) generated against specific peptide sequences corresponding to amino acids 306-318 of human HOX11

  • Antibodies generated against synthetic peptides of human TLX1

• Species reactivity: Most available antibodies show reactivity against human, mouse, and rat HOX11 proteins, with predicted cross-reactivity to other species including bovine, chicken, chimpanzee, canine, and Xenopus in some cases .

• Application-specific formulations: Antibodies optimized for particular applications like Western blotting and immunohistochemistry (IHC) with specific recommended dilutions for each application .

What are the standard applications for HOX11 antibodies?

HOX11 antibodies are employed in several research applications, with Western blotting and immunohistochemistry being the most common:

• Western Blotting: For detecting HOX11 protein expression in cell and tissue lysates, typically used at dilutions of 1:1000-1:3000 for certain antibodies (e.g., NBP3-03317) or 1-3 μg/ml for others (e.g., NB100-56424) . This application allows quantitative assessment of HOX11 protein levels across different experimental conditions.

• Immunohistochemistry (IHC): For visualizing HOX11 expression patterns in tissue sections, with recommended dilutions typically between 1:10-1:50. This is particularly useful for analyzing expression in cancer tissues such as human liver cancer, where HOX11 is expected to localize primarily to the nucleus .

• Research on leukemia/lymphoma: HOX11 antibodies are valuable tools for studying T-cell acute lymphoblastic leukemia, where HOX11 expression has prognostic significance .

• Developmental biology studies: For investigating the role of HOX11 in embryonic development, particularly in skeletal formation and spleen development .

What positive controls should be used when validating HOX11 antibodies?

When validating HOX11 antibodies for experimental use, selecting appropriate positive controls is essential:

• Cell lines: Human liver cancer cell lines are recommended as positive controls for HOX11 expression in IHC applications . Western blot analyses have confirmed HOX11 expression in human, mouse, and rat liver cell lysates .

• Tissue samples: Liver tissues from human, mouse, and rat sources have been validated as positive controls for HOX11 antibody testing .

• Recombinant proteins: Purified recombinant HOX11 protein can serve as a definitive positive control, particularly when troubleshooting new antibody lots or experimental conditions.

• T-ALL patient samples: For cancer research applications, T-ALL samples with confirmed HOX11 overexpression (particularly those with known chromosomal translocations involving 10q24) serve as relevant positive controls .

How can researchers optimize Western blot protocols for HOX11 detection?

Optimizing Western blot protocols for HOX11 detection requires attention to several critical parameters:

• Sample preparation:

  • Use 25 μg of total protein per lane for cell line extracts

  • Include protease inhibitors in lysis buffers to prevent HOX11 degradation

  • For nuclear proteins like HOX11, consider using nuclear extraction protocols rather than whole-cell lysates to enrich for the target protein

• Blocking and antibody conditions:

  • Use 3% nonfat dry milk in TBST as blocking buffer

  • Apply HOX11 primary antibody at carefully optimized dilutions:

    • 1:1000-1:2000 for antibodies like NBP3-03317

    • 1-3 μg/ml for antibodies like NB100-56424

  • Incubate primary antibody overnight at 4°C for optimal signal-to-noise ratio

  • Use appropriate HRP-conjugated secondary antibodies (e.g., HRP Goat Anti-Rabbit IgG) at 1:10000 dilution

• Detection method:

  • ECL Basic Kit is sufficient for standard detection

  • For low abundance samples, consider enhanced chemiluminescence reagents or increased exposure times

• Controls:

  • Include positive controls (human, mouse, or rat liver cell lysates)

  • Include a loading control protein (β-actin, GAPDH) to normalize expression levels

A typical Western blot result should show HOX11 protein bands in human, mouse, and rat liver cell lysates when using antibodies at the recommended concentrations .

What are the technical considerations for using HOX11 antibodies in chromatin immunoprecipitation (ChIP) assays?

Chromatin immunoprecipitation with HOX11 antibodies presents unique challenges due to the transcription factor's properties:

• Cross-linking optimization:

  • Standard 1% formaldehyde cross-linking may be insufficient for capturing transient HOX11-DNA interactions

  • Consider dual cross-linking approaches with additional protein-protein cross-linkers like DSG (disuccinimidyl glutarate) before formaldehyde treatment

• Antibody selection considerations:

  • Choose antibodies validated for immunoprecipitation applications

  • Consider epitope accessibility in the cross-linked chromatin context

  • For tagged HOX11 constructs, commercial anti-tag antibodies (e.g., anti-FLAG for Hoxa11-3xFLAG models) often provide higher specificity than anti-HOX11 antibodies

• Modern alternatives to traditional ChIP:

  • The CUT&RUN (Cleavage Under Targets and Release Using Nuclease) technique has been successfully employed to confirm HOX11 binding to a known Six2 enhancer in developing kidney tissues using tagged HOX11 alleles

  • This approach requires less input material and often yields better signal-to-noise ratios than traditional ChIP

• Analysis validation:

  • Include known HOX11 binding sites as positive controls, such as the validated Six2 enhancer

  • Account for the generally AT-rich binding motifs of HOX proteins in data analysis

  • Consider performing parallel ChIP-seq experiments with antibodies against known HOX11 cofactors to identify high-confidence binding sites

The recently generated Hoxa11-3xFLAG and Hoxd11-3xFLAG mouse models offer powerful tools for HOX11 ChIP studies by circumventing the limitations of direct HOX11 antibodies .

How can HOX11 expression analysis be integrated into T-ALL prognosis research?

Integrating HOX11 expression analysis into T-ALL prognosis research requires sophisticated methodological approaches:

• Quantitative expression analysis:

  • Real-time quantitative reverse-transcriptase PCR (qRT-PCR) provides a sensitive method for measuring HOX11 expression levels in patient samples

  • Research has established classification thresholds: high expression (19.7% of pediatric T-ALL cases) versus low expression (28.9% of cases)

  • Standardization of housekeeping genes and calculation methods is essential for inter-laboratory comparisons

• Correlation with clinical outcomes:

  • Studies have shown that high HOX11 expression correlates with better clinical outcomes in specific patient subgroups

  • In a cohort of 20 high-risk T-ALL patients treated on CCG-1901 protocol from the Children's Cancer Group, HOX11 expression conferred a statistically significant prognostic advantage (P=0.01)

  • For all patient groups combined, a trend toward better outcomes was observed but did not reach statistical significance

• Cytogenetic correlation:

  • Direct cytogenetic analysis should be performed to identify chromosomal abnormalities at 10q24

  • Interestingly, only 2/16 specimens with HOX11 expression exhibited abnormalities at 10q24, suggesting alternative mechanisms for HOX11 deregulation beyond gross chromosomal translocations

• Multiparameter analysis:

  • Combine HOX11 expression data with other prognostic markers

  • Consider multivariate analysis to determine the independent prognostic value of HOX11 expression

  • Integrate with minimal residual disease (MRD) monitoring for comprehensive risk assessment

This methodological approach enables researchers to effectively investigate HOX11's role as a prognostic biomarker in T-ALL and explore the mechanisms underlying its association with clinical outcomes.

What strategies exist for studying HOX11 target genes in developmental contexts?

Investigating HOX11 target genes in developmental contexts requires specialized approaches:

• Genetically modified mouse models:

  • Epitope-tagged HOX11 alleles: Recently generated Hoxa11-3xFLAG and Hoxd11-3xFLAG mouse models enable efficient immunoprecipitation and chromatin binding studies without the limitations of direct HOX11 antibodies

  • Cre-inducible systems: The Hoxa11-CreER mouse model allows for lineage tracing of Hox11-expressing cells in vivo, enabling the study of cell fate decisions controlled by HOX11

• Genome-wide binding profiling:

  • CUT&RUN analysis using tagged HOX11 alleles has confirmed binding to known enhancers like the Six2 enhancer in developing kidney

  • The combination of Hoxa11FLAG/FLAG and Hoxd11FLAG/FLAG alleles allows for comprehensive mapping of HOX11 binding sites across different developmental stages and tissues

• Functional validation approaches:

  • Cross-reference binding data with tissue-specific transcriptome analysis to identify direct targets

  • Use CRISPR-Cas9 editing to mutate putative HOX11 binding sites and assess the functional impact on target gene expression

  • Employ reporter assays with wild-type and mutated enhancer elements to confirm direct regulation

• Developmental context considerations:

  • HOX11 functions are highly tissue-specific, with distinct roles in skeletal development, spleen formation, and neuronal fate specification

  • Temporal dynamics of binding should be analyzed across developmental stages

  • Combinatorial binding with cofactors significantly influences target selection and regulatory outcomes

This integrated approach allows researchers to move beyond correlative studies to establish causal relationships between HOX11 binding and target gene regulation in specific developmental contexts.

How can researchers address non-specific binding issues with HOX11 antibodies?

Non-specific binding is a common challenge with HOX11 antibodies due to the highly conserved homeodomain. Several strategies can minimize this issue:

• Antibody selection and validation:

  • Choose antibodies raised against unique regions outside the conserved homeodomain when possible

  • Validate specificity using HOX11 knockout or knockdown controls

  • Consider using epitope-tagged HOX11 models and corresponding tag antibodies for higher specificity

• Optimization of blocking conditions:

  • For Western blot applications, 3% nonfat dry milk in TBST has been validated as an effective blocking buffer

  • For IHC applications, test alternative blocking agents (BSA, serum, commercial blocking reagents) if background issues persist

  • Extend blocking times for tissues with high endogenous biotin or peroxidase activity

• Secondary antibody considerations:

  • Pre-adsorb secondary antibodies against tissues or species causing cross-reactivity

  • Consider using secondary antibodies specifically designed to minimize cross-reactivity with endogenous immunoglobulins

• Additional controls:

  • Include isotype controls at equivalent concentrations to assess non-specific binding

  • Perform peptide competition assays with the immunizing peptide to confirm specificity

  • Test antibodies on a panel of tissues/cells with known HOX11 expression profiles

When persistent non-specific binding occurs despite optimization, molecular techniques like CRISPR-Cas9 gene editing to generate epitope-tagged HOX11 variants may provide a superior alternative to direct HOX11 antibodies .

What are the advantages and limitations of different HOX11 antibody formats?

Different HOX11 antibody formats offer distinct advantages and limitations for research applications:

Researchers should select the appropriate antibody format based on their specific experimental requirements, considering factors such as detection method, sample type, and desired sensitivity and specificity levels.

What quality control metrics should researchers apply when validating new HOX11 antibody lots?

Rigorous quality control is essential when validating new HOX11 antibody lots to ensure experimental reproducibility:

• Basic characterization tests:

  • Protein concentration verification

  • SDS-PAGE analysis to confirm antibody purity

  • ELISA against immunizing antigen to verify immunoreactivity

• Application-specific validation:

  • Western blot using consistent positive controls (liver cell lysates from human, mouse, and rat)

  • Side-by-side comparison with previous antibody lots

  • Verification of expected band sizes and signal intensities

• Specificity assessments:

  • Peptide competition assays

  • Testing on samples with genetic HOX11 manipulation (knockout, knockdown, overexpression)

  • Cross-reactivity testing against related HOX family members

• Sensitivity evaluation:

  • Titration series to determine optimal working concentrations

  • Limit of detection determination using purified recombinant HOX11 protein

  • Signal-to-noise ratio quantification across different antibody concentrations

• Documentation practices:

  • Record lot numbers, dates, and validation results

  • Maintain images of validation experiments

  • Document optimal working conditions for each application

Implementing these quality control metrics ensures consistent performance across experiments and facilitates troubleshooting when unexpected results occur.

How are HOX11 antibodies being used to explore the role of HOX11 in adult tissue maintenance?

Recent research has revealed that HOX11 plays ongoing roles in adult tissues beyond its well-established developmental functions:

• Adult skeletal maintenance:

  • HOX11-expressing cells function as skeletal stem cells that self-renew throughout life

  • Antibody-based lineage tracing in adult tissues reveals the persistence of HOX11-positive stem cell populations

  • Immunohistochemical staining with HOX11 antibodies can identify these stem cell populations in adult skeletal tissues

• Regenerative medicine applications:

  • HOX11-positive cells may serve as targets for therapeutic interventions in skeletal disorders

  • Antibody-based cell sorting can isolate HOX11-expressing populations for ex vivo expansion and reimplantation

  • Monitoring HOX11 expression during tissue regeneration provides insights into healing mechanisms

• Aging-related studies:

  • Changes in HOX11 expression patterns during aging may contribute to skeletal fragility

  • Comparative immunostaining across age groups can reveal shifts in HOX11-positive cell distributions

  • Correlation of HOX11 expression with bone density and quality metrics informs age-related pathologies

• Methodological approaches:

  • Single-cell analysis combining HOX11 antibody labeling with other markers identifies subpopulations with specific functions

  • In situ approaches preserve spatial information critical for understanding HOX11 function in tissue architecture

  • Temporal studies using inducible genetic models complemented by antibody detection reveal dynamic regulation

These emerging applications highlight the importance of HOX11 antibodies for understanding not only developmental processes but also homeostatic mechanisms in adult tissues .

What new technologies are enabling more sensitive detection of HOX11 in research samples?

Technological advances are enhancing the sensitivity and specificity of HOX11 detection:

• Proximity ligation assay (PLA):

  • Enables detection of protein-protein interactions involving HOX11

  • Offers single-molecule sensitivity by generating fluorescent signals only when two antibodies bind in close proximity

  • Particularly valuable for studying HOX11 interactions with cofactors in different cellular contexts

• Single-cell Western blotting:

  • Allows analysis of HOX11 expression in individual cells

  • Overcomes limitations of population averaging in heterogeneous samples

  • Particularly relevant for studying rare HOX11-expressing stem cell populations

• Mass cytometry (CyTOF):

  • Enables multiplexed detection of HOX11 alongside dozens of other markers

  • Uses metal-tagged antibodies instead of fluorophores to eliminate spectral overlap issues

  • Provides high-dimensional data for comprehensive characterization of HOX11-expressing cells

• Highly multiplexed imaging:

  • Techniques like CODEX, MIBI, and Imaging Mass Cytometry allow spatial analysis of HOX11 expression

  • Preserves tissue architecture while enabling detection of numerous markers simultaneously

  • Reveals HOX11 expression in the context of the tissue microenvironment

• In situ sequencing approaches:

  • Combines antibody detection with transcriptomic analysis

  • Correlates HOX11 protein expression with target gene activation

  • Provides spatial context for understanding HOX11 function

These technologies are particularly valuable for studying HOX11 in complex tissues where expression may be restricted to specific cell types or developmental niches.

How might genome-wide binding studies of HOX11 transform our understanding of its function?

The recently developed Hoxa11-3xFLAG and Hoxd11-3xFLAG mouse models enable comprehensive genome-wide binding studies that promise to transform our understanding of HOX11 function :

• Identification of direct target genes:

  • CUT&RUN analysis has already confirmed binding to a known Six2 enhancer in developing kidney

  • Genome-wide binding profiles across different tissues and developmental stages will reveal tissue-specific regulatory networks

  • Integration with chromatin accessibility data can identify pioneer factor activities

• Cooperative binding mechanisms:

  • HOX proteins typically function in complexes with cofactors like TALE homeodomain proteins

  • Genome-wide binding studies can reveal co-binding patterns and composite motifs

  • Comparison of binding profiles between Hoxa11 and Hoxd11 will elucidate paralog-specific functions

• Temporal dynamics of regulation:

  • Sequential ChIP studies across developmental timepoints can reveal dynamic changes in binding patterns

  • Correlation with gene expression changes will identify activating versus repressive functions

  • Analysis of binding site turnover during evolution provides insights into conserved regulatory modules

• Technical advances required:

  • Integration of multiple data types (ChIP-seq, RNA-seq, ATAC-seq) for comprehensive understanding

  • Development of computational methods to distinguish functional from non-functional binding events

  • Application of single-cell approaches to resolve cellular heterogeneity

These genome-wide studies will address longstanding questions about HOX target specificity, particularly how highly conserved homeodomain proteins achieve specific regulatory outcomes despite recognizing similar DNA motifs.

What are the implications of HOX11 expression in cancer beyond T-ALL?

While HOX11's role in T-ALL is well-established, emerging research suggests broader implications in cancer biology:

• Potential roles in solid tumors:

  • Immunohistochemistry with HOX11 antibodies has identified expression in liver cancer samples

  • The relationship between HOX11 expression and prognosis in solid tumors remains to be thoroughly investigated

  • Further research using validated antibodies is needed to establish expression patterns across cancer types

• Stem cell connection:

  • HOX11's role in skeletal stem cells suggests potential involvement in cancer stem cell populations

  • Antibody-based isolation of HOX11-positive cells from tumors may reveal stem-like properties

  • Single-cell analyses combining HOX11 detection with stemness markers could identify therapeutically relevant subpopulations

• Paradoxical prognostic associations:

  • In T-ALL, HOX11 expression is associated with favorable outcomes in some patient cohorts

  • This contrasts with many oncogenes that typically confer worse prognosis

  • Understanding the mechanisms behind this paradoxical association may reveal novel therapeutic strategies

• Methodological considerations for cancer research:

  • Rigorous quantitative assessment of HOX11 expression levels is critical

  • Standardized threshold determination for "high" versus "low" expression

  • Integration with other molecular markers for comprehensive tumor characterization

Research into HOX11's broader roles in cancer biology will benefit from the antibody resources and mouse models described in the literature, enabling more precise characterization of expression patterns and functional consequences.